Logo image
I kappa B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappa B in the central nervous system
Journal article   Open access   Peer reviewed

I kappa B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappa B in the central nervous system

Jenni Raasch, Nicolas Zeller, Geert van Loo, Doron Merkler, Alexander Mildner, Daniel Erny, Klaus-Peter Knobeloch, John R. Bethea, Ari Waisman, Markus Knust, …
Brain (London, England : 1878), v 134(4), pp 1184-1198
01 Apr 2011
PMID: 21310728
url
https://academic.oup.com/brain/article-pdf/134/4/1184/13734853/awq359.pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1093/brain/awq359View
Published, Version of Record (VoR) Open

Abstract

Clinical Neurology Life Sciences & Biomedicine Neurosciences Neurosciences & Neurology Science & Technology
The I kappa B kinase complex induces nuclear factor kappa B activation and has recently been recognized as a key player of autoimmunity in the central nervous system. Notably, I kappa B kinase/nuclear factor kappa B signalling regulates peripheral myelin formation by Schwann cells, however, its role in myelin formation in the central nervous system during health and disease is largely unknown. Surprisingly, we found that brain-specific I kappa B kinase 2 expression is dispensable for proper myelin assembly and repair in the central nervous system, but instead plays a fundamental role for the loss of myelin in the cuprizone model. During toxic demyelination, inhibition of nuclear factor kappa B activation by conditional ablation of I kappa B kinase 2 resulted in strong preservation of central nervous system myelin, reduced expression of proinflammatory mediators and a significantly attenuated glial response. Importantly, I kappa B kinase 2 depletion in astrocytes, but not in oligodendrocytes, was sufficient to protect mice from myelin loss. Our results reveal a crucial role of glial cell-specific I kappa B kinase 2/nuclear factor kappa B signalling for oligodendrocyte damage during toxic demyelination. Thus, therapies targeting I kappa B kinase 2 function in non-neuronal cells may represent a promising strategy for the treatment of distinct demyelinating central nervous system diseases.

Metrics

14 Record Views
94 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Clinical Neurology
Neurosciences
Logo image